ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SN. Smith & Nephew Plc

1,023.50
-1.50 (-0.15%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50 -0.15% 1,023.50 1,024.50 1,025.00 1,027.50 1,019.50 1,023.50 2,425,622 16:35:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Ortho,prosth,surg Appl,suply 5.55B 263M 0.3011 34.04 8.95B
Smith & Nephew Plc is listed in the Ortho,prosth,surg Appl,suply sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 1,025p. Over the last year, Smith & Nephew shares have traded in a share price range of 887.00p to 1,315.00p.

Smith & Nephew currently has 873,398,889 shares in issue. The market capitalisation of Smith & Nephew is £8.95 billion. Smith & Nephew has a price to earnings ratio (PE ratio) of 34.04.

Smith & Nephew Share Discussion Threads

Showing 1276 to 1299 of 1325 messages
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older
DateSubjectAuthorDiscuss
21/3/2024
17:29
Let's hope that cleared out the seller
edwardt
21/3/2024
16:39
This stock is completely out of favour.
CEO needs the boot.

justiceforthemany
06/3/2024
13:38
Interested to read this in Citywire
quote
he market has an ‘unconscious bias’ against Smith & Nephew (SN) and always assumes the worst about the medical technology company, says Liberum.

Analyst Seb Jantet retained his ‘buy’ recommendation and target price of £12.85 on the Citywire Elite Companies AA-rated provider of hip and knee implants, which rose 0.3% to £10.46 on Tuesday.

‘We are slightly perplexed by the market’s reaction to Smith & Nephew’s full-year results,’ Jantet said.

‘Trading was in line and there was a solid guide for full year 2024. And while the initial share price reaction was positive, the shares fell sharply over the next few days.

‘Understandable given Smith & Nephew’s track record, but it is this unconscious bias that is creating an interesting disconnect between the valuation and the fundamentals,’ said Jantet.

He added that ‘both the revenue and margin guides are achievable’ and said the ‘discount to peers is too high’.

cerrito
01/3/2024
16:42
So who's bothered to contact the CEO?
If you're a stakeholder you certainly should.

justiceforthemany
29/2/2024
17:46
CEO is on very thin ice here. Has been for a while. The discount to peers like Stryker is stark, assuming EPSA for 2024 comes in around 85c; 15x P/E.
Despite the Covid backlog shares remain super depressed and half their pre covid value.
CEO email below
Deepak.nath@smith-nephew.com

justiceforthemany
29/2/2024
12:41
Bought s small amount.
essentialinvestor
28/2/2024
23:21
Smith and nephew price about 13 dollars ,stryker 350 dollars so maybe no .
lonrho
28/2/2024
21:25
Stryker eps 8.25 dollarsS.N eps 0.828 centsSo maybe, yes.
pdriccio
28/2/2024
17:49
Stryker trades at 35x earnings.
This stock at 15x earnings.
Fair?

justiceforthemany
28/2/2024
09:15
Haha. Gone well that one. As has Hunting
dope007
28/2/2024
09:04
Come on Dope you got bab right - time you got in here!
Suet

suetballs
28/2/2024
08:44
Getting tempted here as the UK mkt continues to perform awfully
dope007
27/2/2024
16:14
This used to trade at 20-25x earnings.
Now down at 15x
Appears bids for the company have been and are being with held IMO.

justiceforthemany
27/2/2024
12:00
Eek. Presumably peeps selling on the rise.
Suet

suetballs
27/2/2024
08:41
bit of a relief those results. 20% margin target re-affirmed. just maybe we could be onto a decent recovery here.
edwardt
31/1/2024
17:36
stryker smashed it.
edwardt
18/12/2023
00:40
Exactly ; pinch of salt. They all talk their own book.
philanderer
17/12/2023
22:56
Do UBS and Goldman know what they are talking about with target price differential of neay 30% from current share price. That says a lot about professional analysis.
shabirm
15/12/2023
15:56
or........

UBS cuts Smith & Nephew price target to 1,090 (1,150) pence - 'neutral'

philanderer
10/11/2023
11:07
Goldman Sachs starts Smith & Nephew with 'buy' - price target 1,400 pence
philanderer
02/11/2023
13:27
Suet: I agree re undervaluation. We live in hope.
keyno
02/11/2023
12:21
Justice, so around £9 was a decent entry - you can thank me later ;
essentialinvestor
02/11/2023
12:19
Still got an awful long way to rally, cost savings look good for the margin..........
chrisdgb
02/11/2023
12:07
Why was it allowed to crash 30% in a month? Just because a hedge fund opened a short?
Corrupt market.

justiceforthemany
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older

Your Recent History

Delayed Upgrade Clock